In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novate: Re-Newing The IVC Filter Market

Executive Summary

Serial medtech entrepreneurs Chas Taylor and Paul Gilson founded Novate Medical Ltd. to develop a bioconvertible inferior vena cava filter – it protects patients from pulmonary embolisms during a critical interval, then integrates into the vessel wall. There is no need to retrieve it, a benefit that goes far beyond the economics of avoiding a second procedure.

You may also be interested in...



BTG Enters IVC Market With $150M Novate Bolt-On

The diversified UK firm is betting $20m upfront and up to $150m total on a novel inferior vena cava filter technology.

Veryan Medical: Improving Stent Performance With 3-D, Helical Geometry

Vein Device Companies Dig Deeper

Vein diseases such as deep vein thrombosis, pulmonary embolism and chronic venous insufficiency have historically been the province of drug therapies, but they shouldn't be, according to the clinical socieities and medical device companies that are trying to create a groundswell in interventional vein treatments. The field is starting to organize: on the clinical side, the first clinical trials ever to pit devices against drugs for DVT are in progress. At the same time, Covidien has drawn attention to the business opportunities in the field by acquiring three companies with venous devices.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel